Advertisement
U.S. Markets closed

Adocia SA (ADOC.PA)

Paris - Paris Delayed Price. Currency in EUR
7.49+1.30 (+21.00%)
At close: 05:35PM CEST
Full screen
Loading interactive chart...
  • Business Wire

    ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs for the Treatment of Obesity and Diabetes Using Its BioChaperone® Platform

    LYON, France, October 15, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company specialized in the discovery and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it has filed patents of stable formulations of hormone combinations for the treatment of obesity and diabetes using its BioChaperone® platform.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024

    LYON, France, October 08, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions